KRAS MUTATIONS AND RESISTANCE TO ANTI-EGFR TREATMENT

摘要

The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-EGFR treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance. The present disclosure also provides kits for use in the methods described herein.

主权项

1. A method of predicting if a subject being treated for colorectal cancer with anti-EGFR therapy will develop drug resistance, the method comprising,
obtaining a biological sample from said subject, and assaying said sample for an alteration in KRAS expression, wherein if an alteration in KRAS expression is detected, the subject is more likely to develop drug resistance to said anti-EGFR therapy.